Health communication in and out of public health emergencies: to persuade or to inform?

Ethics Evidence-informed health policy Health communication Health education Health information Health promotion Infodemic Persuasion Risk communication

Journal

Health research policy and systems
ISSN: 1478-4505
Titre abrégé: Health Res Policy Syst
Pays: England
ID NLM: 101170481

Informations de publication

Date de publication:
05 Mar 2022
Historique:
received: 07 12 2021
accepted: 11 02 2022
entrez: 6 3 2022
pubmed: 7 3 2022
medline: 9 3 2022
Statut: epublish

Résumé

Much health communication during the COVID-19 pandemic has been designed to persuade people more than to inform them. For example, messages like "masks save lives" are intended to compel people to wear face masks, not to enable them to make an informed decision about whether to wear a face mask or to understand the justification for a mask mandate. Both persuading people and informing them are reasonable goals for health communication. However, those goals can sometimes be in conflict. In this article, we discuss potential conflicts between seeking to persuade or to inform people, the use of spin to persuade people, the ethics of persuasion, and implications for health communication in the context of the pandemic and generally. Decisions to persuade people rather than enable them to make an informed choice may be justified, but the basis for those decisions should be transparent and the evidence should not be distorted. We suggest nine principles to guide decisions by health authorities about whether to try to persuade people.

Identifiants

pubmed: 35248064
doi: 10.1186/s12961-022-00828-z
pii: 10.1186/s12961-022-00828-z
pmc: PMC8897761
doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

28

Informations de copyright

© 2022. The Author(s).

Références

BMJ. 2016 Jun 28;353:i2016
pubmed: 27353417
Ann Intern Med. 2021 Oct;174(10):1456-1457
pubmed: 34370512
R Soc Open Sci. 2020 Oct 14;7(10):201199
pubmed: 33204475
BMJ. 2014 Dec 09;349:g7015
pubmed: 25498121
BMJ Evid Based Med. 2020 Oct 19;:
pubmed: 33077575
Nature. 2019 Aug;572(7769):303-306
pubmed: 31406318
Euro Surveill. 2013 Jun 20;18(25):
pubmed: 23806298
Eff Clin Pract. 2001 Mar-Apr;4(2):76-9
pubmed: 11329989
Cochrane Database Syst Rev. 2017 Feb 07;2:CD011787
pubmed: 28169420
BMJ Open. 2017 Nov 16;7(11):e018593
pubmed: 29150475
Patient Educ Couns. 2012 Jan;86(1):9-18
pubmed: 21474265
Ann Intern Med. 2007 Feb 20;146(4):256-65
pubmed: 17310049
Can J Public Health. 2010 Sep-Oct;101(5):396-8
pubmed: 21214055
Nat Med. 2021 Jan;27(1):10-13
pubmed: 33340033
BMJ. 2015 Feb 05;350:h658
pubmed: 25655431
J Med Ethics. 2021 Feb 25;:
pubmed: 33632729
Proc Natl Acad Sci U S A. 2020 Apr 7;117(14):7672-7683
pubmed: 32205438
Front Commun (Lausanne). 2020 Jun;5:
pubmed: 33594338
Health Educ Behav. 2000 Oct;27(5):591-615
pubmed: 11009129
J Clin Epidemiol. 2016 Apr;72:98-106
pubmed: 25618534
Kennedy Inst Ethics J. 2012 Dec;22(4):345-66
pubmed: 23420941
Lancet. 2010 Oct 9;376(9748):1261-71
pubmed: 20933263
Am J Bioeth. 2021 Jan;21(1):22-24
pubmed: 33373581
Euro Surveill. 2020 May;25(19):
pubmed: 32431291
PLoS One. 2021 Nov 17;16(11):e0259048
pubmed: 34788299
Health Care Anal. 2016 Mar;24(1):24-46
pubmed: 24100936
BMJ. 2021 May 26;373:n1207
pubmed: 34039589
Cochrane Database Syst Rev. 2011 Mar 16;(3):CD006776
pubmed: 21412897
Psychol Health. 2021 Mar 6;:1-18
pubmed: 33678078
Med Health Care Philos. 2012 Nov;15(4):373-82
pubmed: 22042598
BMJ Open. 2020 Jul 21;10(7):e036348
pubmed: 32699132
N Engl J Med. 2005 Jan 27;352(4):325-8
pubmed: 15673797
Health Promot J Austr. 2015 Dec;26(3):246-254
pubmed: 26608800
Cogn Res Princ Implic. 2020 Nov 11;5(1):56
pubmed: 33175284
Risk Manag Healthc Policy. 2021 Jan 26;14:293-302
pubmed: 33542664
F1000Res. 2021 Jun 1;10:433
pubmed: 35083033
PLoS Med. 2012;9(9):e1001308
pubmed: 22984354
Tidsskr Nor Laegeforen. 2020 Feb 16;140(3):
pubmed: 32105039
J Clin Epidemiol. 2013 Jul;66(7):726-35
pubmed: 23570745
Cochrane Database Syst Rev. 2020 Apr 20;4:CD004407
pubmed: 32309885
Monash Bioeth Rev. 2014 Mar-Jun;32(1-2):106-20
pubmed: 25434067
PLoS Biol. 2017 Sep 11;15(9):e2002173
pubmed: 28892482
Health Commun. 2021 Jan;36(1):116-123
pubmed: 33191801
Ann Intern Med. 2009 Apr 21;150(8):516-27
pubmed: 19221371

Auteurs

Andrew D Oxman (AD)

Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Skøyen, Postboks 222, 0213, Oslo, Norway. oxman@online.no.

Atle Fretheim (A)

Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Skøyen, Postboks 222, 0213, Oslo, Norway.
Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.

Simon Lewin (S)

Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Skøyen, Postboks 222, 0213, Oslo, Norway.
Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa.

Signe Flottorp (S)

Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Skøyen, Postboks 222, 0213, Oslo, Norway.
Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.

Claire Glenton (C)

Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Skøyen, Postboks 222, 0213, Oslo, Norway.

Arnfinn Helleve (A)

Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Skøyen, Postboks 222, 0213, Oslo, Norway.
Centre for Evaluation of Public Health Measures, Norwegian Institute of Public Health, Oslo, Norway.

Didrik Frimann Vestrheim (DF)

Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Skøyen, Postboks 222, 0213, Oslo, Norway.

Bjørn Gunnar Iversen (BG)

Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Skøyen, Postboks 222, 0213, Oslo, Norway.

Sarah E Rosenbaum (SE)

Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Skøyen, Postboks 222, 0213, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH